HVC
CPRX

Healthcare Value Capital’s Catalyst Pharmaceutical CPRX Stock Holding History

Healthcare Value Capital’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-50,000
Closed -$149K – 37
2014
Q4 		$149K Buy
+50,000
New +$137K 0.27% 26

Other funds holding CPRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
CCA
Catalyst Capital Advisors Huntington, New York $5.37B AUM 18.53% 1-Year Est. Return

Healthcare Value Capital's CPRX Position: Q1 2015 in Review

Healthcare Value Capital sold out of Catalyst Pharmaceutical (CPRX) in Q1 2015, closing a stake of 50,000 shares — an estimated $149K sold.

Healthcare Value Capital first reported a position in CPRX in Q4 2014 and held it in 1 quarter. The position peaked at $149K in Q4 2014. 66 funds tracked by Wall St. Rank hold CPRX as of Q1 2015.

  • Healthcare Value Capital reported no remaining Catalyst Pharmaceutical position as of Q1 2015 after selling out during the quarter.
  • Healthcare Value Capital sold 50,000 Catalyst Pharmaceutical shares in Q1 2015, an estimated $149K.
  • Healthcare Value Capital first reported a position in Catalyst Pharmaceutical in Q4 2014 and held it in 1 quarter.
  • Healthcare Value Capital's Catalyst Pharmaceutical position peaked at $149K in Q4 2014.
  • 66 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2015.

Based on Healthcare Value Capital's 13F filing for Q1 2015, filed 14 May 2015.